Brief: Abionyx Pharma H1 Revenue Up At 2.5 Millon Euros

Abionyx Pharma SA

29/09/2022 18:28

Sept 29 (Reuters) -  ABNX.PA :
    * H1 OPERATING RESULTS WENT FROM A LOSS OF €2,586K AT JUNE
30,
2021 TO A LOSS OF €2,455K AT JUNE 30, 2022 
    * H1 FINANCIAL RESULT SHOWS A DEFICIT OF €95K AS OF JUNE 30,
2022,
COMPARED TO A SURPLUS OF €41K IN THE FIRST HALF OF 2021 
    * H1 NET LOSS AMOUNTS TO €2,550K AS OF JUNE 30, 2022,
COMPARED TO
A LOSS OF €2,546K AS OF JUNE 30, 2021 
    * THE GROUP RECORDED CONSOLIDATED HALF-YEAR REVENUES OF
€2,630K,
AN INCREASE COMPARED TO JUNE 30, 2021
    * PHASE 2A CLINICAL TRIAL WITH CER-001 IS EXPECTED TO BE
COMPLETED
SOON IN SEPTIC PATIENTS AT HIGH RISK OF DEVELOPING ACUTE KIDNEY
INJURY

        
 Source text for Eikon:  ID:nBwbtllMBa 
 Further company coverage:  ABNX.PA  
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))